Comparing patient access to pharmaceuticals in the UK and US.
The debate on access to new drugs has focused on the time lag between applications for approval and granting of marketing authorisation. This delay was identified as the first barrier with respect to patient access to new drugs, encompassing the hurdles of safety, efficacy and quality. Additional barriers have since been identified. These pertain to reimbursement and pricing of approved drugs, the so-called fourth and fifth hurdles.
Version: za2963e q8za7 q8zb0 q8zc8 q8zd8 q8zed q8zf3 q8zge